Canadian Pharmacists Journal - May/June 2019 - 185

PRaCtiCeReView
Sciences (Santschi), HES-SO University of Applied Sciences and Arts of Western Switzerland, Switzerland. Contact v.santschi@
ecolelasource.ch.
Conflicts of interest and source of funding: The authors report no specific funding in relation to this research and no conflicts of
interest to disclose.

References
1. Centers for Disease Control and Prevention. Vital Signs:
high blood pressure and cholesterol. July 23, 2013. Available:
https://www.cdc.gov/VitalSigns/pdf/2011-02-vitalsigns.pdf
(accessed Oct. 8, 2018).
2. Centers for Disease Control and Prevention. Vital Signs:
high blood pressure and cholesterol. September 6, 2018.
Available: https://www.cdc.gov/vitalsigns/pdf/vs-0918-mill
ion-hearts-H.pdf (accessed Oct. 8, 2018).
3. Kearney PM, Whelton M, Reynolds K, et al. Worldwide
prevalence of hypertension: a systematic review. J Hypertens
2004;22(1):11-9.

9. Santschi V, Chiolero A, Colosimo AL, et al. Improving
blood pressure control through pharmacist interventions:
a meta-analysis of randomized controlled trials. J Am Heart
Assoc 2014;3(2):e000718.
10. Marra C, Johnston K, Santschi V, Tsuyuki RT. Cost-effectiveness of pharmacist care for managing hypertension in
Canada. Can Pharm J (Ott)2017;150(3):184-97.
11. Lamb SA, Al Hamarneh YN, Houle SKD, et al. Hypertension Canada's 2017 guidelines for diagnosis, risk assessment,
prevention and treatment of hypertension in adults for pharmacists: an update. Can Pharm J (Ott) 2018;151(1):33-42.

4. Olsen MH, Angell SY, Asma S, et al. A call to action
and a lifecourse strategy to address the global burden
of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet
2016;388(10060):2665-712.
5. Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US
pharmacists' effect as team members on patient care:
systematic review and meta-analyses. Med Care 2010;48(10):
923-33.
6. Santschi V, Tsuyuki RT, Paradis G. Evidence for pharmacist care in the management of hypertension. Can Pharm J
(Ott) 2015;148(1):13-6.
7. de Barra M, Scott CL, Scott NW, et al. Pharmacist services
for non-hospitalised patients. Cochrane Database Syst Rev
2018;9:Cd013102.
8. Santschi V, Chiolero A, Burnand B, et al. Impact of pharmacist care in the management of cardiovascular disease risk
factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med 2011;171(16):1441-53.

12. Tsuyuki RT, Berg A, Khan NA. The ultimate opportunity for advancing pharmacy practice. Can Pharm J
(Ott)2017;150(4):225-6.
13. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/
AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/
PCNA guideline for the prevention, detection, evaluation
and management of high blood pressure in adults: a report of
the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018;138(17):e484-e594.
14. Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention and treatment of hypertension in adults.
Can J Cardiol 2017;33(5):557-76.
15. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH
guidelines for the management of arterial hypertension: the
task force for the management of arterial hypertension of the
European Society of Cardiology and the European Society of
Hypertension. J Hypertens 2018;36(10):1953-2041.

C P J / R P C  *  M ay / J u n e  2 0 1 9  *  V O L  1 5 2 ,  N O  3 

185
https://www.cdc.gov/VitalSigns/pdf/2011-02-vitalsigns.pdf https://www.cdc.gov/vitalsigns/pdf/vs-0918-million-hearts-H.pdf https://www.cdc.gov/vitalsigns/pdf/vs-0918-million-hearts-H.pdf
Canadian Pharmacists Journal - May/June 2019

Table of Contents for the Digital Edition of Canadian Pharmacists Journal - May/June 2019
